- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02975310
In-clinic Endoscopic Polypectomy for Chronic Sinusitis With Nasal Polyps
Endoscopic Polypectomy Performed In Clinic for Chronic Rhinosinusitis With Polyps: The EPIC Randomised Controlled Trial
Study Overview
Status
Conditions
Detailed Description
Chronic rhinosinusitis (CRS) is common, with a Canadian prevalence of 5%, and associated with significant morbidity having a health state utility value equivalent to end-stage renal disease. Understandably, CRS impairs workplace productivity but that productivity substantially increases following surgical treatment.
However, the wait time to receive surgical treatment (ESS) maybe up to 8 months or longer, with a cost to the Government of $3500/ESS procedure. The annual direct cost of CRS is estimated at $860 million with an overall financial impact of 1.3 billion dollars per year for Canada. Endoscopic polypectomy in clinic (EPIC), a potential disruptive innovation, is a drastically deescalated form of ESS performed in clinic instead of the operating room. EPIC appears to provide quality of life (QofL) improvement equivalent to that reported for ESS. EPIC has a shorter wait time and lower cost to a government, i.e. nearly one-tenth of ESS or about $450. A pilot economic evaluation study demonstrated that EPIC was cost-effective compared to ESS. This has created a controversy about which treatment should be employed for these patients. Further, a recent Cochrane review identified the need for high-quality randomised controlled trials to determine if ESS has additional benefit over polypectomy as there is currently insufficient evidence to draw conclusions about the superiority of polypectomy or ESS for the management of CRS with polyps.
The proposed national multicenter randomised controlled trial will determine whether EPIC is non-inferior to the current treatment standard, ESS, in QofL improvement for patients with CRS with polyps. It will also assess the cost-effectiveness of performing EPIC in place of ESS. The investigators hypothesize that EPIC will be non-inferior to ESS for QofL improvement while reducing health care cost. This would imply that EPIC is a dominant strategy and that the ESS strategy represents over-treatment in this patient population. The study findings would position EPIC into the current CRS treatment paradigm thereby transforming care and reducing costs both nationally and internationally.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Andrea Lasso, MSc
- Phone Number: 10222 6137985555
- Email: alasso@toh.ca
Study Locations
-
-
British Columbia
-
Vancouver, British Columbia, Canada
- Recruiting
- Vancouver General Hospital
-
Contact:
- Kelly Nguyen
- Email: kelly.nguyen@alumni.ubc.ca
-
-
Ontario
-
London, Ontario, Canada, N6A 4V2
- Recruiting
- St. Joseph's Hospital London
-
Contact:
- Taciano Rocha
-
Contact:
-
Ottawa, Ontario, Canada, K1Y 1J8
- Recruiting
- Ottawa Hospital Research Institute
-
Contact:
- Andrea Lasso, MSc
- Phone Number: 10222 613-798-5555
- Email: alasso@toh.ca
-
-
Quebec
-
Montréal, Quebec, Canada, H4A 3J1
- Recruiting
- McGill University Health Center
-
Contact:
- Marc Tewfik
-
Contact:
- Email: marc.tewfik@mcgill.ca
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18 years or older
- Diagnosis of chronic rhinosinusitis with polyps requiring surgical treatment after having been treated with medical therapy as designated by the Canadian clinical practice guidelines for acute and chronic sinusitis. 15
- Bilateral nasal polyps present of Grade ≥ 2 on each side as determined by the Lildholdt scale score measured by nasal endoscopy at the screening visit.
- Must have nasal blockage score greater than or equal to 2 on the sinonasal outcome test SNOT-22 at the screening visit.
- Must have an American Society of Anesthesiologists physical status PS3 classification or less.
- Participants with comorbid asthma or chronic obstructive pulmonary disease (COPD) must have stable disease with no exacerbations (no emergency room visits, hospitalisations, or oral or parental steroid use for these lower respiratory conditions) within 3 months before the screening visit.
- Must be capable, in the opinion of the investigator, of providing informed consent to participate in the study. Participants must sign an informed consent document indicating that they understand the purpose of and procedures of the study and are willing to participate in the study.
Exclusion Criteria:
- Women who are pregnant or breast feeding as per patient's report
- Patients with hyperplastic polyps or polyps large enough that they result in external nasal deformity
- Facial pain/pressure score higher than 2 on the sinonasal outcome test SNOT-22 at the screening visit.
- History of any surgical procedure that prevents the ability to accurately grade the nasal polyps
- Participants who will not be able to complete the follow-up appointments/evaluations
- Have significant oral structural abnormalities, e.g. unrepaired cleft palate
- Septal deviation requiring correction in order to perform either EPIC or ESS procedures
- Diagnosis of an immunodeficiency or immunocompromised state
- Diagnosis of cystic fibrosis
- Diagnosis of allergic fungal sinusitis
- Contraindication to the use of oral corticosteroids (e.g. uncontrolled diabetes, congestive heart failure, uncontrolled hypertension, known renal insufficiency, known peptic ulcer disease, known glaucoma, pregnancy)
- History of either Churg-Strauss syndrome, primary ciliary dyskinesia, or vasculitis (e.g. granulomatosis with polyangiitis(GPA))
- Allergy, hypersensitivity, or contraindication to the use of local or topical lidocaine anesthetics, nasal topical 1:1000 adrenaline, nasal decongestants, nasal steroid spray
- Any serious or unstable concurrent disease, psychiatric disorder, or any significant condition that, in the opinion of the investigator, could confound the results of the study or could interfere with the participant's participation or compliance with the study
- A recent (within 1 year of the screening visit) clinically significant history of drug or alcohol abuse, or dependence that, in the opinion of the investigator could interfere with the participant's participation or compliance with the study
- Inability to read and understand English
- Any medical condition that in the opinion of the investigator would interfere with the treatment
- Any participant who is unfit to undergo surgery under general anesthesia
- Current participation in another clinical trial at the time of the screening visit.
- Participant is unable to undergo an awake procedure
- Diagnosis or Aspirin Exacerbated Respiratory Disease (AERD)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Endoscopic polypectomy in clinic (EPIC)
Patients assigned to this arm of the study will undergo the In Clinic Polypectomy Performed in Clinic
|
The experimental intervention is endoscopic polypectomy performed in clinic (EPIC) where nasal polyps are removed using a microdebrider under local and topical anesthesia in the outpatient clinic.
EPIC will be performed under topical and local anesthesia in a clinic setting
|
Active Comparator: Endoscopic Sinus Surgery (ESS)
Patients assigned to this arm will undergo endoscopic sinus surgery (ESS),
|
The control intervention is endoscopic sinus surgery (ESS), a minimally invasive procedure that is the current standard that involves polypectomy with a microdebrider as well as sinus ostia enlargement of the affected sinuses performed in the operating room under general anesthesia.
ESS will be performed under general anesthesia in the operating room
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Sinonasal Outcome Test-22 (SNOT-22)
Time Frame: 3 months
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Peak Nasal Inspiratory Flow (PNIF):
Time Frame: 3 months
|
3 months
|
|
Iowa Satisfaction with Anesthesia Scale (ISAS)
Time Frame: 3 months
|
Patient satisfaction with anesthesia for the treatment procedure
|
3 months
|
Work Productivity and Activity Impairment: Specific Health Problem (WPAI:SHP)
Time Frame: 3 months
|
Work Impairment related to chronic rhinosinusitis
|
3 months
|
EQ-5D-5L
Time Frame: 3 months
|
Quality of Life
|
3 months
|
Participant Health Resource Consumption Survey
Time Frame: 3 months
|
Individual Health Resource Consumption
|
3 months
|
Adverse Events
Time Frame: 3 months
|
3 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Lund-Kennedy Endoscopic Scoring Scale
Time Frame: 3 months
|
Endoscopic inflammation of the nose and paranasal sinuses after treatment
|
3 months
|
Visual Analogue Scale (VAS) for satisfaction with assigned procedure
Time Frame: 3 months
|
Satisfaction with assigned procedure
|
3 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Shaun Kilty, MD, The Ottawa Hospital Research Institute
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CTO-0801
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sinusitis
-
Loma Linda UniversityWithdrawnChronic Sinus Disease | Chronic Sinusitis, Ethmoidal | Chronic Sinusitis, Sphenoidal | Chronic Sinusitis - Maxillary Bilateral | Chronic Sinusitis - Frontoethmoidal
-
LifeBridge HealthUnknownChronic Sinusitis | Nasal Polyps | Chronic Sinusitis, Ethmoidal | Chronic Sinusitis, Sphenoidal | Chronic Sinusitis - Frontoethmoidal | Chronic Sinusitis - Ethmoidal, Posterior | Chronic Sinusitis - Ethmoidal Anterior | Nasal Polyp - PosteriorUnited States
-
Collin County Ear Nose & ThroatIntersect ENTCompletedChronic Sinusitis, EthmoidalUnited States
-
Tampere University HospitalRecruitingMaxillary Sinusitis | Eustachian Tube Dysfunction | Sinusitis, Chronic | Sinusitis RecurrentFinland
-
STS MedicalNot yet recruitingChronic Sinusitis, Ethmoidal
-
St. Louis UniversityTerminatedStent | Sinusitis, FrontalUnited States
-
Oulu University HospitalTampere University HospitalRecruitingSinusitis | Maxillary Sinusitis | Sinusitis, AcuteFinland
-
Cairo UniversityNot yet recruitingChronic Maxillary Sinusitis
-
Centre Hospitalier Intercommunal CreteilActive, not recruitingChronic Maxillary SinusitisFrance
-
DeyCompletedACUTE SINUSITISUnited States
Clinical Trials on Endoscopic polypectomy in clinic (EPIC)
-
Ottawa Hospital Research InstituteActive, not recruiting
-
Yuqi HeRecruitingAdenomatous PolypsChina
-
St John of God Hospital, ViennaCompleted
-
University of British ColumbiaRecruitingColon Adenoma | Colon Polyp | Colon LesionCanada
-
Ningbo No. 1 HospitalRecruitingHaemorrhage | Pedunculated Colorectal PolypsChina
-
Showa Inan General HospitalCompleted
-
Universitätsklinikum Hamburg-EppendorfTerminatedColorectal Adenomatous Polyp | Colorectal Adenoma With Mild Dysplasia | Colorectal Adenoma With Severe Dysplasia | Colorectal Low Grade Intraepithelial Neoplasia | Colorectal High Grade Intraepithelial NeoplasiaGermany, United Kingdom
-
Wake Forest University Health SciencesNational Cancer Institute (NCI); Washington University School of Medicine; University...Active, not recruitingColorectal Neoplasms | Hodgkin Disease | Breast Neoplasm | Endometrial Neoplasms | Non Hodgkin Lymphoma | Prostatic NeoplasmUnited States
-
Uijeongbu St. Mary HospitalCompleted
-
Africa Mental Health FoundationUniversity of British Columbia; Grand Challenges Canada; Nextgenu.org; CliniX Healthcare... and other collaboratorsCompletedSubstance-Related Disorders | Alcohol-Related Disorders | Social StigmaKenya